GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vicore Pharma Holding AB (OSTO:VICO) » Definitions » Cyclically Adjusted PB Ratio

Vicore Pharma Holding AB (OSTO:VICO) Cyclically Adjusted PB Ratio : 1.40 (As of Jan. 18, 2025)


View and export this data going back to 2015. Start your Free Trial

What is Vicore Pharma Holding AB Cyclically Adjusted PB Ratio?

As of today (2025-01-18), Vicore Pharma Holding AB's current share price is kr8.69. Vicore Pharma Holding AB's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2024 was kr6.20. Vicore Pharma Holding AB's Cyclically Adjusted PB Ratio for today is 1.40.

The historical rank and industry rank for Vicore Pharma Holding AB's Cyclically Adjusted PB Ratio or its related term are showing as below:

OSTO:VICO' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 1.11   Med: 2.54   Max: 3.58
Current: 1.54

During the past years, Vicore Pharma Holding AB's highest Cyclically Adjusted PB Ratio was 3.58. The lowest was 1.11. And the median was 2.54.

OSTO:VICO's Cyclically Adjusted PB Ratio is ranked better than
51.26% of 595 companies
in the Biotechnology industry
Industry Median: 1.57 vs OSTO:VICO: 1.54

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Vicore Pharma Holding AB's adjusted book value per share data for the three months ended in Sep. 2024 was kr3.289. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is kr6.20 for the trailing ten years ended in Sep. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Vicore Pharma Holding AB Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Vicore Pharma Holding AB's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vicore Pharma Holding AB Cyclically Adjusted PB Ratio Chart

Vicore Pharma Holding AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Vicore Pharma Holding AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 2.28 3.31 1.16

Competitive Comparison of Vicore Pharma Holding AB's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Vicore Pharma Holding AB's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vicore Pharma Holding AB's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vicore Pharma Holding AB's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Vicore Pharma Holding AB's Cyclically Adjusted PB Ratio falls into.



Vicore Pharma Holding AB Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Vicore Pharma Holding AB's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=8.69/6.2
=1.40

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vicore Pharma Holding AB's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2024 is calculated as:

For example, Vicore Pharma Holding AB's adjusted Book Value per Share data for the three months ended in Sep. 2024 was:

Adj_Book=Book Value per Share/CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=3.289/132.3043*132.3043
=3.289

Current CPI (Sep. 2024) = 132.3043.

Vicore Pharma Holding AB Quarterly Data

Book Value per Share CPI Adj_Book
201412 3.139 100.225 4.144
201503 0.000 99.950 0.000
201506 4.623 99.995 6.117
201509 0.000 100.228 0.000
201512 5.660 100.276 7.468
201603 5.549 100.751 7.287
201606 5.457 101.019 7.147
201609 5.347 101.138 6.995
201612 2.182 102.022 2.830
201703 5.488 102.022 7.117
201706 6.529 102.752 8.407
201709 6.438 103.279 8.247
201712 3.100 103.793 3.952
201803 6.312 103.962 8.033
201806 6.588 104.875 8.311
201809 5.692 105.679 7.126
201812 8.426 105.912 10.526
201903 6.423 105.886 8.026
201906 5.826 106.742 7.221
201909 5.310 107.214 6.553
201912 6.236 107.766 7.656
202003 5.717 106.563 7.098
202006 5.263 107.498 6.478
202009 6.635 107.635 8.156
202012 5.709 108.296 6.975
202103 8.530 108.360 10.415
202106 7.582 108.928 9.209
202109 6.272 110.338 7.521
202112 5.197 112.486 6.113
202203 3.949 114.825 4.550
202206 3.089 118.384 3.452
202209 2.176 122.296 2.354
202212 3.436 126.365 3.597
202303 2.670 127.042 2.781
202306 3.228 129.407 3.300
202309 4.933 130.224 5.012
202312 3.966 131.912 3.978
202403 4.257 132.205 4.260
202406 3.788 132.716 3.776
202409 3.289 132.304 3.289

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Vicore Pharma Holding AB  (OSTO:VICO) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Vicore Pharma Holding AB Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Vicore Pharma Holding AB's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Vicore Pharma Holding AB Business Description

Traded in Other Exchanges
Address
Kornhamnstorg 53, Stockholm, SWE, 111 27
Vicore Pharma Holding AB is as a clinical-stage pharmaceutical company focused on severe lung diseases. The company is establishing a portfolio in respiratory diseases, including idiopathic pulmonary fibrosis (IPF). Its C21 is a small molecule angiotensin II type 2 receptor agonist (ATRAG) currently in phase 2a development for IPF. The company also has an investigational medical device in clinical development namely, Almee which is a digital therapeutic leveraging cognitive behavioral therapy created to address the psychological impact of living with pulmonary fibrosis.

Vicore Pharma Holding AB Headlines

No Headlines